Brown, Jennifer R <br/><br/>
A phase 2 study of concurrent fludarabine and rituximab for the treatment of marginal zone lymphomas.  [electronic resource] 

 -  British journal of haematology  Jun 2009 
 - 741-8 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, N.I.H., Extramural 
<br/><br/><label>ISSN: </label>1365-2141 
<br/><br/><label>Standard No.: </label>10.1111/j.1365-2141.2009.07677.x  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Aged<br/>Aged, 80 and over<br/>Antibodies, Monoclonal--adverse effects<br/>Antibodies, Monoclonal, Murine-Derived<br/>Antineoplastic Combined Chemotherapy Protocols--adverse effects<br/>Disease-Free Survival<br/>Female<br/>Follow-Up Studies<br/>Humans<br/>Lymphoma--drug therapy<br/>Lymphoma, B-Cell, Marginal Zone--drug therapy<br/>Lymphoproliferative Disorders--drug therapy<br/>Male<br/>Middle Aged<br/>Prospective Studies<br/>Rituximab<br/>Survival Rate<br/>Vidarabine--adverse effects